Immunostimulating agents: What next? A review of their present and potential medical applications

European Journal of Biochemistry

Volumn 242, Issue 1, 1996, Pages 1-19

  Werner, Georges H ^a   Jollès, Pierre ^b  

^a CNRS   (France)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

Adjuvant; Biological response modifier; Immunomodulator; Immunopharmacology; Immunostimulant

Indexed keywords

ALPHA TOCOPHEROL; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTIBODY; BACTERIAL PROTEIN; BCG VACCINE; CARBOXYETHYLGERMANIUM SESQUIOXIDE; GLUCAN; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; KRESTIN; LENTINAN; LEVAMISOLE; LIPID A DERIVATIVE; LIPOPOLYSACCHARIDE; MURABUTIDE; MURAMYL DIPEPTIDE DERIVATIVE; MURAMYL TRIPEPTIDE; MUROCTASIN; PICIBANIL; RETINOL; SCHIZOPHYLLAN; SCLEROGLUCAN; SELENIUM; TETRAMISOLE; THYMOMODULIN; THYMOSTIMULIN; THYMUS FACTOR; TUFTSIN; UNINDEXED DRUG; VACCINE;

BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BACTERIA (MICROORGANISMS);

EID: 0029985065     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-1033.1996.0001r.x     Document Type: Review

References (156)

1. Langman, R. E. (1989) The immune system, Academic Press Inc., New York, p. 310.
2. Fridman, W. H. (1991) Le cerveau mobile, Hermann publishers, Paris, p. 216.
3. Black, P. H. (1994) Central nervous system-immune system interactions: psychoneuroendocrinology of stress and its immune consequences, Antimicrob. Agents Chemother. 38, 1-6.
4. Ramon, G. (1926) Procédés pour accroître la production des antitoxines, Ann. Inst. Pasteur (Paris) 40, 1-10.
5. Metchnikoff, E. (1892) Leçons sur la pathologie comparée de l'inflammation, G. Masson publishers, Paris, p. 239.
6. Coley, W. B. (1895) The treatment of inoperable malignant tumors with the toxins of erysipelas and Bacillus prodigiosus, Med. Rec. Ann. 47, 65-70.
7. Hall, S. S. (1995) IL-12 at the crossroads, Science 268, 1432-1434.
8. Henderson, B. & Blake, S. (1992) Therapeutic potential of cytokine manipulation, Trends Pharmacol, Sci. 13, 145-152.
9. McIntyre, C. A. & Rees, R. C. (1992) Cytokines and inflammation, Drug News Perspect. 5, 207-213.
10. Brakenhoff, J. P. J. (1995) Interleukin-6 receptor antagonists, Drug News Perspect. 8, 397-403.
11. Lefebvre d'Hellencourt, C., Diaw, L. & Guenounou, M. (1995) Immunomodulation by cytokine antisense oligonucleotides, Eur. Cytokine Network 6, 7-19.
12. Allison, A. C., Lafferty, K. J. & Fliri, H. (1993) Immunosuppressive and antiinflammatory drugs, Ann. N. Y. Acad. Sci. 696, 1-421.
13. St Georgiev, V. & Yamaguchi, H. (1993) Immunomodulating drugs, Ann. N.Y. Acad. Sci. 685, 1-812.
14. Klingemann, H. G. (1995) Update on immunosuppressive drugs, Drug News Perspect. 8, 303-309.
15. St Georgiev, V. (1991) Immunomodulating peptides of natural and synthetic origin, Med. Res. Rev. 11, 81-119.
16. St Georgiev, V. (1990) Synthetic immunomodulating agents, Med. Res. Rev. 10, 371-409.
17. Chirigos, M. A. (1992) Immunomodulators: current and future development and application, Thymus 19, S7-S20.
18. Hadden, J. W. (1993) Immunostimulants, Immunol. Today 14, 275-280.
19. Biozzi, G., Benacerraf, F. B., Grumbach, F., Halpern, B. N., Levaditi, J. & Rist, N. (1954) Etude de l'activité granulopéxique du système réticulo-endothelial au cours de l'infection tuberculeuse expérimentale de la souris, Ann. Inst. Pasteur (Paris) 87, 291-300.
20. Dubos, R. J. & Schaedler, R. W. (1957) Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections. I. Protective effects, J. Exp. Med. 106, 703-719.
21. Biozzi, G., Stiffel, C., Halpern, B. N. & Mouton, D. (1959) Effet de l'inoculation du bacille de Calmette-Guérin sur le développement de la tumeur ascitique d'Ehrlich chez la souris, C.R. Soc. Biol. (Paris) 153, 987-989.
22. Mathé, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. L., Hayat, M. & de Vassal, F. (1969) Active immunotherapy for acute lymphoid leukemia, Lancet 1, 697-699.
23. Morales, A., Eidinger, D. & Bruce, A. W. (1976) Intercavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors, J. Urol. 116, 180-183.
24. Morales, A. (1984) Long term results and complications of intercavitary bacillus Calmette-Guérin therapy for bladder cancer, J. Urol. 132, 457-459.
25. Lamm, D. L. (1995) Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy, Eur. Urol. suppl. 1, p. 27, Karger, Basel.
26. Jackson, A. M. & James, K. (1994) Understanding the most successful immunotherapy of cancer. The Immunologist 2, 208-215.
27. Freund, J., Casals, J. & Hosmer, E. P. (1937) Sensitization and antibody formation after injection of killed tubercle bacilli and paraffin oil, Proc. Soc. Exp. Biol. Med. 37, 509-513.
28. Ishida, N. & Hoshino, T. A. (1985) Streptococcal preparation as a potent biological response modifier (OK-432), Excerpta Med., 2nd edn, 1-69.
29. Tsuchiya, I., Kasahara, T., Yamashita, K., Ko, Y. C., Kanazawa, K., Matsushima, K. & Mukaida, N. (1993) Induction of inflammatory cytokines in the pleural effusion of cancer patients after the administration of an immunomodulator OK-432: role of IL-8 for neutrophil infiltration, Cytokine 5, 595-603.
30. Robinson, C. (1994) Subreum (OM-89), Drugs Future 19, 845-849.
31. Beuth, J., Ko, H. L., Roszkowski, W. & Pulverer, G. (1990) Bacteria of physiological microflora liberate immunomodulating peptides, Microecol. Ther. 20, 175-183.
32. Bocci, V. (1992) The neglected organ: bacterial flora has a crucial immunomodulatory role, Perspect. Biol. Med. 35, 251-260.
33. Takada, H. & Kotani, S. (1989) Structural requirements of lipid A for endotoxicity and other biological activities, CRC Crit. Rev. Microbiol. 16, 477-523.
34. Ribi, E., Amano, K., Cantrell, J. L., Schwartzman, S. M., Parker, R. & Takayama, K. (1982) Preparation and antitumor activity of nontoxic lipid A, Cancer Immunol. Immunother. 12, 91-102.
35. Yao, Z., Elliott, G. T. & Gross, G. J. (1994) Monophosphoryl lipid A: a new approach for cardioprotection, Drug News Perspect. 7, 96-102.
36. Brown, J. M., Grosso, M. A., Terada, L. S., Whitman, G. J. R., Banerjee, A., White, C. W., Harken, A. H. & Repine, J. E. (1989) Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts, Proc. Natl Acad. Sci. USA 86, 2516-2520.
37. Neway, T., Boulouis, H. J., Thibault, D. & Pilet, C. (1992) Activité des glycopeptidolipides polaires de Mycobacterium chelonae sur la restauration d'une leucopénie chimio-induite chez la souris, C.R. Acad. Sci. Paris 315, 13-19.
38. Lagrange, P. H., Fourgeaud, M., Neway, T. & Pilet, C. (1995) Les glycopeptidolipides polaires mycobactériens augmentent la résistance de la candidose expérimentale. C.R. Acad. Sci. Paris 318, 359-365.
39. Ellouz, T., Adam, A., Ciorbaru, R. & Lederer, E. (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives, Biochem. Biophys. Res. Commun. 59, 1317-1325.
40. Baschang, G. (1989) Muramylpeptides and lipopeptides: studies towards immunostimulants, Tetrahedron 45, 6331-6360.
41. Bahr, G. M., Darcissac, E., Bevec, D., Dukor, P. & Chedid, L. (1995) Immunopharmacological activities and clinical development of muramylpeptides with particular emphasis on murabutide, Int. J. Immunopharmacol. 17, 117-131.
42. Lidgate, D. M. & Byars, N. E. (1995) Development of an emulsion-based muralyldipeptide adjuvant formulation for vaccines, in Vaccine design, the subunit and adjuvant approach (Powell, M. F. & Newman, M. J., eds) pp. 313-324, Plenum Press, New York.
43. Azuma, I. (1992) Development of the cytokine inducer romurtide: experimental studies and clinical applications, Trends Pharmacol. Sci. 13, 425-428.
44. Namba, K., Otani, T. & Osada, Y. (1994) Enhancement of platelet recovery in X-irradiated guinea pigs by romurtide, a synthetic muramyldipeptide derivative, Blood 83, 2480-2488.
45. Fidler, I. J., Sone, S., Fogler, W. E. & Barnes, Z. L. (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyldipeptide, Proc. Natl Acad. Sci. USA 78, 1680-1684.
46. Gay, B., Cardot, J. M., Schnell, C., Van Hoogevest, P. & Gygax, D. (1993) Comparative pharmacokinetics of free muramyltripeptide phosphatidyl-ethanolamine (MTP-PtdEtn) and liposomal MTP-PE, J. Pharm. Sci. 82, 997-1001.
47. Kleinerman, E. S., Raymond, A. K., Bucana, C. D., Jaffe, N., Harris, M. B., Krakoff, I. H., Benjamin, R. & Fidler, I. J. (1992) Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyltripeptide, Cancer Immunol. Immunother. 34, 211-220.
48. Killion, J. J., Brown, D. R., Wilson, M. R., Lloyd, M. M. & Fidler, I. J. (1994) Prevention of chemotherapy or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyltripeptide, Oncol. Res. 6, 357-364.
49. O'Reilly, T. & Zak, O. (1992) Enhancement of the effectiveness of antimicrobial therapy by muramylpeptide immunomodulators, Clin. Infect. Dis. 14, 1100-1109.
50. Migliore-Samour, D., Floc'h, F., Maral, R., Werner, G. H. & Jollès, P. (1977) Adjuvant activities of chemically modified water-soluble substances from Mycobacterium tuberculosis, Immunology 33, 477-484.
51. Migliore-Samour, D., Bouchaudon, J., Floc'h, F., Zerial, A., Ninet, L., Werner, G. H. & Jollès, P. (1979) Propriétés immunostimulantes et adjuvantes d'un lipopeptide de faible poids moléculaire, C.R. Acad. Sci. Paris 289D, 473-476.
52. Migliore-Samour, D., Bouchaudon, J., Floc'h, F., Zerial, A., Ninet, E., Werner, G. H. & Jollès, P. (1980) A short lipopeptide, representative of a new family of immunological adjuvants devoid of sugar, Life Sci. 26, 883-888.
53. Floc'h, F., Bouchaudon, J., Fizames, C., Zerial, A., Dutruc-Rosset, G. & Werner, G. H. (1984) Lauroyltetrapeptide (R. P. 40639) and related lipopeptides: a novel class of synthetic immunomodulating agents. Drugs Future 9, 763-776.
54. Floc'h, F. & Poirier, J. (1988) Immunopotentiating activities of a low molecular mass lipopeptide, R.P. 56142. Studies in infectious models, Int. J. Immunopharmacol. 10, 863-873.
55. Floc'h, F., Poirier, J., Fizames, C. & Woehrle, R. (1987) Pimelautide (R. P. 40639) from experimental results to clinical trials: an illustration, in Immunostimulants now and tomorrow (Azuma, I. & Jollès, G., eds) pp. 183-204, Japanese Scientific Societies Press, Tokyo and Springer-Verlag, Berlin.
56. Migliore-Samour, D., Delaforge, M., Jaouen, M., Mansuy, D. & Jollès, P. (1989) In vivo effects of immunomodulating lipopeptides on mouse liver microsomal cytochromes P-450 and on paracetamol-induced toxicity, Experientia (Basel) 45, 882-886.
57. Migliore-Samour, D., Bousseau, A., Caillaud, J. M., Naussac, A., Sedqi, M., Ferradini, C. & Jollès, P. (1993) Radioprotective effects of the immunostimulating lauroylpeptide L tri P (R.P. 56142), Experientia (Basel) 49, 160-166.
58. Sedqi, M., Delaforge, M., Mansuy, D., Martin, B., Jollès, P. & Migliore-Samour, D. (1995) Immunostimulating lipopeptide, L tri P (R.P. 56142); comparison of the effect on hepatic cytochrome P-450 modulation and radioprotection in male and female of three mouse strains, Experientia (Basel) 51, 790-798.
59. Deprez, B., Gras-Masse, H., Martinon, F., Gomard, E., Levy, J. P. & Tartar, A. (1995) Pimelautide or trimexautide as built-in adjuvants associated with an HIV-1-derived peptide: synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated-response, J. Med. Chem. 38, 459-465.
60. Goto, T., Nakahara, K., Nishiura, T., Hashimoto, M., Kino, T., Kuroda, Y., Okuhara, M., Kohsaka, M., Aoki, H. & Imanaka, H. (1982) Studies on a new immunoactive peptide, FK-156 II. Fermentation, extraction and chemical and biological characterization, J. Antibiot. 35, 1286-1292.
61. Goto, T. & Aoki, H. (1987) The immunomodulatory activities of acylpeptides, in Immunostimulants, now and tomorrow (Azuma, I. & Jollès, G., eds) pp. 99-108, Japanese Scientific Societies Press, Tokyo and Springer-Verlag, Berlin.
62. Kusumi, T., Yamada, A., Cao, M., Tanaka, A., Takenada, H. & Imanishi, J. (1989) Enhancing effects of immunoactive peptide FR 48127 on immunological responses to vaccination by inactivated influenza virus, Vaccine 7, 351-356.
63. Mine, Y., Watanabe, Y., Tawara, S., Yokota, Y., Nishida, M., Goto, S. & Kuwahara, S. (1983) Immunoactive peptides, FK-156 and FK-565. III. Enhancement of host defense mechanisms against infection, J Antibiot. 36, 1059-1066.
64. Inamura, N., Nakahara, K., Kito, T., Gotoh, T., Kawamura, I., Aoki, H. & Sone, S. (1985) Activation of tumoricidal properties in macrophages and inhibition of experimentally-induced murine metastases by a new synthetic acyltripeptide, FK-565, J. Biol. Resp. Mod. 4, 408-417.
65. Puri, A., Rizvi, S. Y., Haq, W., Guru, P. Y., Kundu, B., Saxena, R. P., Shukla, R., Mathur, K. B. & Saxena, K. C. (1993) Immunostimulant activity of a novel lipopeptide and its protective action against Leishmania donovani, Immunopharmacol. Immunotoxicol. 15, 539-556.
66. Sidwell, R. W., Smee, D. F. Huffman, J. H., Bailey, K. W., Warren, R. P., Burger, R. A. & Penney, C. L. (1995) Antiviral activity of an immunomodulatory lipophilic desmuramyldipeptide analog, Antiviral. Res. 26, 145-159.
67. Reitermann, A., Metzger, J., Wiesmüller, K. H., Jung, G. & Bessler, W. G. (1989) Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten, Biol. Chem. Hoppe-Seyler 370, 343-352.
68. Bessler, W. G., Kleine, B., Biesert, L. & Schlecht, S. D. (1990) Bacterial surface components as immunomodulators, in Immunotherapeutic prospects of infectious diseases (Masihi, K. N. & Lange, W., eds) pp. 37-48, Springer-Verlag, Berlin, Heidelberg.
69. Wiesmüller, K. H., Hess, G., Bessler, W. G. & Jung, G. (1990) Diastereomers of tripalmitoyl-S-glyceryl-L-cysteinyl carrier adjuvant systems induce different mitogenic and protective immune responses, in Chirality and biological activity (Holmstedt, B., Frank, H. & Testa, B., eds) pp. 267-272, Alan R. Liss, New York.
70. Loleit, M., Tröger, W., Wiesmüller, K. H., Jung, G., Strecker, M. & Bessler, W. G. (1990) Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation, Biol. Chem. Hoppe-Seyler 371, 967-975.
71. Chihara, G. (1984) Immunopharmacology of lentinan and the glucans, Rev. Immunol. Immunopharmacol. 4, 85-96.
72. Kraus, J. & Franz, G. (1991) β(1-3) glucans: antitumor activity and immunostimulation, in Fungal cell wall and immune response (Latgé, J. P. & Boucias, D., eds) pp. 431-444, Springer-Verlag, Berlin.
73. Trnovec, T. & Hrmova, M. (1993) Immunomodulator polysaccharides: chemistry, disposition and metabolism, Biopharm. & Drug Dispos. 14, 187-195.
74. Goldman, R. C. (1993) Biological response modification by β-D-glucans, Ann. Rep. Med. Chem. 130, 129-138.
75. Pretus, H. A., Ensley, H. E., McNamee, R. B., Jones, E. L., Browder, I. W. & Williams, D. L. (1991) Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan, J. Pharmacol. Exp. Ther. 257, 500-510.
76. Jamas, S., Easson, D. D. Jr & Ostroff, G. R. (1990) PGG, a novel class of macrophage activating immunomodulators, Abstr. Int. Congress. Infect. Dis., no. 698, p. 143.
77. Lagrange, P. H. & Fourgeaud, M. (1991) Enhanced natural resistance against severe disseminated Candida albicans infection in mice treated with betafectin, Int. J. Exp. Clin. Chemother. 4, 48-55.
78. Nicoletti, A., Nicoletti, G., Ferraro, G., Palmieri, G., Mattaboni, P. & Germogli, R. (1992) Preliminary evaluation of immunoadjuvant activity of an orally administered glucan extracted from Candida albicans, Arzneim.-Forsch./Drug Res. 42, 1246-1250.
79. Kobayashi, H., Matsunaga, K. & Fujii, M. (1993) PSK as a chemopreventive agent, Cancer Epidemiol. Biomarkers and Prevention 2, 271-276.
80. Kobayashi, H., Matsunaga, K. & Fujii, M. (1995) Antimetastatic effects of PSK, a protein-bound polysaccharide obtained from basidiomycetes: an overview, Cancer Epidemiol. Biomarkers and Prevention 4, 275-281.
81. Nakazato, H., Koike, A., Saji, S., Ogama, N. & Sakamoto, I. (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343, 1122-1126.
82. Mitomi, T., Tsuchiya, S., Iijima, N., Aso, K., Suzuki, K., Nishiyama, K., Amano, T., Takahashi, T., Murayama, N., Oka, H., Oya, K., Noto, T. & Ogawa, N. (1992) Randomized controlled study on adjuvant immuno-chemotherapy with PSK in curatively resected colorectal cancer. Dis. Colon Rectum 35, 123-130.
83. Franz, G. (1992) Immunomodulation durch Echinacea purpurea und Viscum album, Erfahrungsheilkunde 6, 401-405.
84. Franz, G. (1993) Risiko ohne Nutzen-Nutzen ohne Risiko, am Beispiel von Immunomodulatoren, Therapeutikon 7, 562-568.
85. Chen, J. R., Suetsuna, K. & Yamauchi, F. (1995) Isolation and characterization of immunostimulative peptides from soybean, Nutritional Biochem. 6, 310-313.
86. Werner, G. H. (1987) Immunostimulants: the western scene, in Immunostimulants, now and tomorrow (Azuma, 1. & Jollès, G., eds) pp. 3-39. Springer-Verlag, Berlin, Japan Scientific Societies Press, Tokyo.
87. Perrillo, R. P. & Mason, A. L. (1994) Therapy for hepatitis B virus infection, Gastroenterol. Clin. North Am. 23, 581-601.
88. Handzel, Z. T. & Trainin, N. (1990) Immunomodulation of T-cell deficiency in humans by thymic humoral factor, J. Biol. Response Modif. 9, 269-278.
89. Fiocchi, A., Borella, E., Riva, E. & Arensi, D. (1986) A double-blind clinical trial for the evaluation of the therapeutic effectiveness of a calf thymus derivative (thymomodulin) in children with recurrent respiratory infections, Thymus 8, 331-339.
90. Braga, P. C., Dal Sasso, M., Maci, S., Piatti, G. & Palmieri, R. (1994) Restoration of polymorphonuclear leukocyte function in elderly subjects by thymomodulin, J. Chemother. 6, 354-359.
91. De Mattia, D., Decandia, P., Ferrante, P. & Pace, D. (1993) Effectiveness of thymostimulin and study of lymphocyte-dependent antibacterial activity in children with recurrent respiratory infections, Immunopharmacol. Immunotoxicol. 15, 447-459.
92. Periti, P., Tonelli, F., Mazzei, T. & Ficari, F. (1993) Antimicrobial chemoimmunoprophylaxis in colorectal surgery with cefotetan and thymostimulin: prospective, controlled multicenter study, J. Chemother. 5, 37-42.
93. Miller, M. J. S., Witherly, S. A. & Clark, D. A. (1990) Casein: a milk protein with diverse biologic consequences. Proc. Soc Exp. Biol. Med. 195, 143-159.
94. Jollès, P., Parker, F., Floc'h, F., Migliore-Samour, D., Alliel, P., Zerial, A. & Werner, G. H. (1982) Immunostimulating substances from human casein, J. Immunopharmacol. 3, 363-369.
95. Parker, F., Migliore-Samour, D., Floc'h, F., Zerial, A., Werner, G. H., Jollès, J., Casaretto, M., Zahn, H. & Jollès, P. (1984) Immunostimulating hexapeptide from human casein. Amino acid sequence, synthesis and biological properties, Eur. J. Biochem. 145, 677-682.
96. Berthou, J., Migliore-Samour, D., Lifchitz, A., Delettré, J., Floc'h, F. & Jollès, P. (1987) Immunostimulating properties and three-dimensional structure of two tripeptides from human and cow-caseins, FEBS Lett. 218, 55-58.
97. Gattegno, L., Migliore-Samour, D., Saffar, L. & Jollès, P. (1988) Enhancement of phagocytic activity of human monocyte-macrophage cells by immunostimulating peptides from human casein, Immunol. Lett. 18, 27-31.
98. Ross, A. C. (1992) Vitamin A status: relationship to immunity and the antibody response. Proc. Soc. Exp. Biol. Med. 200, 303-320.
99. Forni, G., Cerruti, S. S., Giovanelli, M., Santoni, A., Martinetto, P. & Vietti, D. (1986) Effect of prolonged administration of low doses of dietary retinoids on cell-mediated immunity and the growth of transplantable tumors in mice, J. Nat. Cancer Inst. 76, 527-533.
100. Lemire, J. M. (1995) Immunomodulatory actions of 1,25-di-hydroxyvitamin D3, J. Steroid Biochem. Mol. Biol. 53, 599-602.
101. Alroy, I., Towers, T. L. & Freedman, L. P. (1995) Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol. Cell. Biol. 15, 5789-5799.
102. Shkalar, G., Schwartz, J. L., Trickler, D. & Reid, S. (1990) Prevention of experimental cancer and immunostimulation by vitamin E (immunosurveillance), J. Oral Pathol. Med. 19, 60-64.
103. Wang, Y. & Watson, R. R. (1994) Ethanol, immune responses and murine AIDS: the role of vitamin E as an immunostimulant and antioxidant, Alcohol 11, 75-84.
104. Labro, M. T. (1993) Immunomodulation by antibacterial agents. Is it clinically relevant? Drugs 45, 319-328.
105. Labro, M. T. (1990) Cefodizime as a biological response modifier: a review of its in vivo, ex vivo and in vitro immunomodulatory properties, J. Antimicrob. Chemother. 26, 37-47.
106. Lianou, P. K., Votta, E. G., Papavassiliou, J. T. & Bassaris, H. P. (1993) In vivo potentiation of polymorphonuclear leukocyte function by ciprofloxacin. J. Chemother. 5, 223-227.
107. Scaglione, F., Ferrara, F., Dugnani, S., Demartini, G., Triscari, F. & Fraschini, F. (1993) Immunostimulation by clarithromycin in healthy volunteers and chronic bronchitis patients. J. Chemother. 5, 228-232.
108. Roy, M., Kiremidjian-Schumacher, L., Wishe, H. I., Cohen, M. W. & Stotzky, G. (1995) Supplementation with selenium restores age-related decline in immune cell function, Proc. Soc. Exp. Biol. Med. 209, 369-375.
109. Roy, M., Kiremidjian-Schumacher, L., Wishe, H. I., Cohen, M. W. & Stotzky, G. (1993) Selenium supplementation enhances the expression of interleukin 2 receptor subunits and internalization of interleukin 2, Proc. Soc. Exp. Biol. Med. 202, 295-299.
110. Roy, M., Kiremidjian-Schumacher, L., Wishe, H. I., Cohen, M. W. & Stotzky, G. (1991) Effect of selenium on the expression of high affinity interleukin 2 receptors, Proc. Soc. Exp. Biol. Med. 200, 36-41.
111. Ishiwata, Y., Suzuki, E., Yokochi, S., Otsuka, T., Tasaka, F., Usuda, H. & Mitani, T. (1994) Studies on the antiviral activity of propagermanium with immunostimulating action. Arzneim.-Forsch./Drug Res. 44, 357-361.
112. Hoshi, A. (1993) Proxigermanium (propagermanium) antiviral immunostimulant, Drugs Future 18, 905-908.
113. Kalechman, Y., Shani, A., Albeck, M., Sotnik-Barkai, I. & Sredni, B. (1993) Increased DNA repair ability after irradiation following treatment with the immunomodulator AS-101, Radiation Res. 136, 197-204.
114. Renoux, G. & Renoux, M. (1971) Effet immunostimulant d'un imidazothiazole dans l'immunisation de la souris contre l'infection par Brucella abortus, C. R. Acad. Sci. Paris D272, 349-350.
115. Borden, E. C., Davies, E. & Chirigos, M. A. (1982) Interim analysis of a trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma, in Immunotherapy of human cancer (Terry, W. D. & Rosenberg, S. A., eds) pp. 231-235, Excerpta Medica, New York.
116. Laurie, J., Moertal, C., Fleming, T. & Wieland, H. (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol. 7, 1447-1456.
117. Kimball, E. S. (1993) Experimental modulation of IL-1 production and cell surface molecule expression by levamisole, Ann. N.Y. Acad. Sci. 685, 259-268.
118. Kurman, M. R. (1993) Recent clinical trials with levamisole, Ann. N.Y. Acad. Sci. 685, 269-277.
119. Wierenga, W. (1993) Overview on the chemistry and immunomodulating properties of novel pyrimidinones, Ann. N.Y. Acad. Sci. 685, 296-300.
120. Sarosdy, M. F. (1993) Bropirimine in bladder cancer: clinical studies, Ann. N.Y. Acad. Sci. 685, 301-308.
121. Anderson, D. W. & Capetola. R. J. (1990) Immunoactive properties of RWJ 21757, a substituted guanosine with adjuvant activity, in Gamete interaction, prospects for immunocontraception (Alexander, N. J., ed.) pp. 523-548, Wiley-Liss, Inc., New York.
122. Chen, R., Goodman, M. G., Argenteri, D., Bell, S. C., Levelle, E. B., Come, J., Goodman, J. H. & Klaubert, D. H. (1994) Guanosine derivatives as immunostimulants: discovery of loxoribine, Nucleosides & Nucleotides 131, 551-562.
123. De Simone, C., Famularo, G., Foresta, P., Albertoni, C. & Arrigoni Martelli, E. (1993) In vivo antitumor activity of the hypoxanthine derivatives St 789 and ST 689, Ann. N.Y. Acad. Sci. 685, 344-346.
124. Sosa, M., Saha, A., Giner-Sorolla, A., Hadden, E. & Hadden, J. W. (1993) Immunopharmacologic properties of inosine 5′-methylmonophosphate (MIMP), Ann. N.Y. Acad. Sci. 685, 458-463.
125. Testerman, T. L., Gerster, J. F., Imbertson, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J., Wagner, T. L. & Tomai, M. A. (1995) Cytokine induction by the immunomodulators imiquimod and S-27609, J. Leukocyte Biol. 58, 365-372.
126. Bernstein, D. I. & Harrison, C. J. (1989) Effects of the immunomodulating agent R 837 on acute and latent herpes simplex virus type 2 infections, Antimicrob. Agents Chemother. 33, 1511-1515.
127. Bernstein, D. I., Miller, R. L. & Harrison, C. J. (1993) Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pig, J. Infect. Dis. 167, 731-735.
128. Gibson, S. J., Imbertson, L. M., Wagner, T. L., Testerman, T. L., Reiter, M. J., Miller, R. L. & Tomai, M. A. (1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609, J. Interferon and Cytokine Res. 15, 537-545.
129. Moyer, M. P., Weber, F. H., Gross, J. L., Isaac, J. W. & Saint Fort, R. (1992) The synthesis and identification of 4,6-diaminoquinoline derivatives as potent immunostimulants, Bioorganic & Med. Chem. Lett. 2, 1589-1594.
130. Moyer, M. P., Weber, F. H. & Gross, J. L. (1992) Structure-activity relationships of imidazo(4,5-f)quinoline partial structures and analogs. Discovery of pyrazolo(3,4-f)quinoline derivatives as potent immunostimulants, J. Med. Chem. 35, 4595-4601.
131. Moyer, M. P., Weber, F. H., Canning, P. C., Gross, J. L. & Saint Fort, R. (1993) Investigation of side-chain SAR, formulation and injection site toleration of pyrazol(3,4-f)quinoline derivatives: a potent series of in vivo active immunostimulants, Bioorganic & Med. Chem. Lett. 3, 1379-1384.
132. Borghi, M. O., Fain, C., Barcellini, W., Del Papa, N., La Rosa, L., Nicoletti, F., Uslenghi, C. & Meroni, P. L. (1994) Ex vivo effect of pidotimod on peripheral blood mononuclear cell immune functions: study of an elderly population, Int. J. Immunother. 10, 35-39.
133. Migliorati, G., D'Adamio, L., Coppi, G., Nicoletti, I. & Riccardi, C. (1992) Pidotimod stimulates natural killer cell activity and inhibits thymocyte cell death, Immunopharmacol. Immunotoxicol. 14, 737-748.
134. Vacca, A., DiStefano, R., Serio, G. & Damacco, F. (1993) Stimulation of residual B-cell immunity in nude mice by pidotimod: an immuno-histological study. Int. J. Immunother. 9, 85-93.
135. Di Marco, R., Condorelli, K., Girardello, R., Uslenghi, C., Chisari, G. & Di Mauro, M. (1992) Increased rate of survival in Streptococcus pneumoniae-infected rats with the new immunomodulator pidotimod, Scand. J. Infect. Dis. 24, 821-823.
136. Capsoni, F., Minonzio, F., Ongari, A. M., Girardello, R., Di Bello, M. & Zanussi, C. (1991) In vitro and ex vivo enhancement of neutrophil functions by PGT/1 A, a new immunostimulating peptide, J. Chemother. 3 (suppl. 3), 147-149.
137. Careddu, P., Alfano, S. & Zavattini, G. (1992) Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood, Adv. Ther. 9, 174-183.
138. Auteris, A., Pasqui, A. L., Gotti, G., Bruni, F., Saletti, M., Di Renzo, M., Bova, G., Borlini, G., Gori, S., Fanetti, G., Campoccia, G., Maggiore, D. & Girardello, R. (1993) The effect of a new biological response modifier (pidotimod) on surgery-associated immunodeficiency, Int. J. Immunother. 9, 95-102.
139. Rhodes, J., Chen, H., Hall, S. R., Beesley, J. E., Jenkins, D. C., Collins, P. & Zheng, B. (1995) Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs, Nature 377, 71-75.
140. High, W. B., Bugelski, P. J., Nichols, M. E., Swift, B. A., Solleveld, H. A. & Badger, A. M. (1994) Effect of a novel azaspirane on the arthritic lesions in the adjuvant Lewis rat. Attenuation of the inflammatory process and preservation of skeletal integrity, J. Rheumatol. 21, 476-483.
141. King, A. G. & Badger, A. M. (1991) Administration of an immunomodulatory azaspirane (SKF 105685) or recombinant human interleukin 1 stimulates myelopoiesis and enhances survival from lethal irradition in C 57 B1/6 mice, Exp. Haematol. 19, 624-628.
142. Audibert, F. M. & Lise, L. D. (1993) Adjuvants: current status, clinical perspectives and future prospects, Immunol. Today 14, 281-284.
143. Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S. & Gupta, C. K. (1993) Adjuvants, a balance between toxicity and adjuvanticity, Vaccine 11, 293-306.
144. Johnson, A. G. (1994) Molecular adjuvants and immunomodulators: new approaches to immunization, Clin. Microbiol. Rev. 7, 277-289.
145. Gupta, K. & Siber, G. R. (1995) Adjuvants for human vaccines. Current status, problems and future prospects, Vaccine 13, 1263-1275.
146. Kensil, C. R., Wu, J. Y. & Soltsysik, S. (1995) Structural and immunological characterization of the vaccine adjuvant QS-21. in Vaccine design, the subunit and adjuvant approach (Powell, M. F. & Newman, M. J., eds) pp. 525-541, Plenum Publishing Corporation, New York.
147. Gjata, B., Hannoun, C., Boulouis, H. J., Neway, T. & Pilet, C. (1994) Activité adjuvante des glycopeptidolipides polaires de Mycobacterium chelonae (GPLp-Mc) sur l'immunogénicité et l'effet protecteur d'un vaccin grippal inactivé, C.R. Acad. Sci. Paris 317, 257-263.
148. Afonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G. & Scott, P. (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major, Science 263, 235-237.
149. Duits, A. J., Van Puijenboek, A., Vermeulen, H., Hofhuis, F. M. A., Van de Winkel, G. J. & Capel, P. J. A. (1993) Immunoadjuvant activity of a liposomal IL-6 formulation, Vaccine 11, 777-781.
150. Murray, P. J., Aldovini, A. & Young, R. A. (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc. Natl Acad. Sci. USA 93, 934-939.
151. Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C. & Fearon, D. T. (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity, Science 271, 348-350.
152. Boon, T. (1995) Tumor antigens and perspectives for cancer immunotherapy, The immunologist 3, 262-263.
153. Williams, N. (1996) An immune boost to the war on cancer, Science 272, 28-30.
154. Kleinerman, E. S., Gano, J. B., Johnston, D. A., Bendamin, R. L. & Jaffe, N. (1995) Efficacy of liposomal muramyl-tripeptide in the treatment of relapsed osteosarcoma, Am. J. Clin. Oncol. Cancer Clin. Trials 18, 93-101.
155. Sigel, K. & Rosenbaum, D. M. (1996) Potential role of hemopoietic cytokines in neuronal survival, Drug News Perspect. 9, 142-148.
156. Thomas, L. (1980) The medusa and the snail, Bantam Books, Toronto, New York, p. 143.